133 related articles for article (PubMed ID: 36398500)
1. Design, synthesis, and biological evaluation of aminopyridine derivatives as novel tropomyosin receptor kinase inhibitors.
Lv R; Wang X; Sun Y; Qin Q; Liu N; Wu T; Sun Y; Yin W; Zhao D; Cheng M
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200438. PubMed ID: 36398500
[TBL] [Abstract][Full Text] [Related]
2. Hydrazide-hydrazones as Small Molecule Tropomyosin Receptor Kina se A (TRKA) Inhibitors: Synthesis, Anticancer Activities,
Alam MS; Lee DU
Med Chem; 2022; 19(1):47-63. PubMed ID: 35490310
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
[TBL] [Abstract][Full Text] [Related]
4. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
[TBL] [Abstract][Full Text] [Related]
5. Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold.
Wu T; Qin Q; Liu N; Zhang C; Lv R; Yin W; Sun Y; Sun Y; Wang R; Zhao D; Cheng M
Eur J Med Chem; 2022 Feb; 230():114096. PubMed ID: 35007864
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors.
Li P; Cai S; Zhao T; Xu L; Guan D; Li J; Zhou J; Zhang H
Bioorg Med Chem Lett; 2021 Dec; 53():128409. PubMed ID: 34628036
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, biological evaluation and pharmacophore model analysis of novel tetrahydropyrrolo[3,4-c]pyrazol derivatives as potential TRKs inhibitors.
Wu T; Zhang C; Lv R; Qin Q; Liu N; Yin W; Wang R; Sun Y; Wang X; Sun Y; Zhao D; Cheng M
Eur J Med Chem; 2021 Nov; 223():113627. PubMed ID: 34171657
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and evaluate of indazolylaminoquinazoline derivatives as potent Tropomyosin receptor kinase (TRK) inhibitors.
Xu Y; Zhao W; Zhang X; Yu X; Chen Y; Wang Z; Chu Y; Zhu X; Zhang P
Bioorg Med Chem; 2024 Feb; 99():117608. PubMed ID: 38271867
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological activity of bicyclic carboxamide derivatives as TRK inhibitors.
Sun M; Cai S; Li P; Zhang F; Zhang H; Zhou J
Bioorg Med Chem; 2020 Dec; 28(23):115811. PubMed ID: 33069129
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
12. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
[TBL] [Abstract][Full Text] [Related]
13. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
14. A novel in-cell ELISA method for screening of compounds inhibiting TRKA phosphorylation, using KM12 cell line harboring TRKA rearrangement.
Pandre MK; Shaik S; Satya Pratap VVV; Yadlapalli P; Yanamandra M; Mitra S
Anal Biochem; 2018 Mar; 545():78-83. PubMed ID: 29360440
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, anticancer, and docking studies of salicyl-hydrazone analogues: A novel series of small potent tropomyosin receptor kinase A inhibitors.
Alam MS; Choi SU; Lee DU
Bioorg Med Chem; 2017 Jan; 25(1):389-396. PubMed ID: 27856237
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.
Li MC; Lin WH; Wang PC; Su YC; Chen PY; Fan CM; Chen CP; Huang CL; Chiu CH; Chang L; Chen CT; Yeh TK; Hsieh HP
Eur J Med Chem; 2021 Nov; 224():113673. PubMed ID: 34303872
[TBL] [Abstract][Full Text] [Related]
17. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
18. Pyrazolo[1,5-a]pyrimidine based Trk inhibitors: Design, synthesis, biological activity evaluation.
Zhang Y; Liu Y; Zhou Y; Zhang Q; Han T; Tang C; Fan W
Bioorg Med Chem Lett; 2021 Jan; 31():127712. PubMed ID: 33246108
[TBL] [Abstract][Full Text] [Related]
19. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer.
Sun Y; Sun Y; Wang L; Wu T; Yin W; Wang J; Xue Y; Qin Q; Sun Y; Yang H; Zhao D; Cheng M
Eur J Med Chem; 2022 Aug; 238():114424. PubMed ID: 35576702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
